Trial Profile
Study of the difference in clinical efficacy by the difference between the GnRH agonist and GnRH antagonist when adding short-term androgen deprivation therapy to definitive radiation therapy for localized intermediate-risk prostate cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2016
Price :
$35
*
At a glance
- Drugs Degarelix (Primary) ; Goserelin
- Indications Prostate cancer
- Focus Therapeutic Use
- 15 Oct 2016 Status changed from not yet recruiting to discontinued.
- 20 Jun 2016 New trial record